about
Resolutive pulmonary endarterectomy in a non-compliant patient with systemic lupus erythematosus and antiphospholipid syndrome.Pulmonary endarterectomy in the elderly: safety, efficacy and risk factors.Long-Term Outcome of Patients With Chronic Thromboembolic Pulmonary Hypertension: Results From an International Prospective Registry.Surgical treatment of chronic thromboembolic pulmonary hypertension.Airway bleeding during pulmonary endarterectomy: the "bubbles" technique.Evolving surgical techniques for pulmonary endarterectomy according to the changing features of chronic thromboembolic pulmonary hypertension patients during 17-year single-center experience.Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry.Surgical treatment of primary pulmonary artery sarcoma.Use of responder threshold criteria to evaluate the response to treatment in the phase III CHEST-1 study.Patients with bicuspid aortic valve are likely to receive an aortic valve prosthesis during prophylactic resection of their ascending aortic aneurysm.Primary pulmonary artery Rosai-Dorfman disease mimicking sarcoma.Long-term Outcome after Pulmonary EndarterectomySuccessful Surgical Management of Invasive Aspergillosis of the Pulmonary ArteriesImpact of high titre of antiphospholipid antibodies on postoperative outcome following pulmonary endarterectomyAortic valve replacement performed twice through ministernotomy 15 years after lung transplantationIt is Worth it to Increase the Use of Extracorporeal Membrane Oxygenation?Pulmonary arterial compliance and exercise capacity after pulmonary endarterectomyChronic thromboembolic pulmonary hypertension: From transplantation to distal pulmonary endarterectomyPulmonary endarterectomy for distal chronic thromboembolic pulmonary hypertension
P50
Q37973694-BD73B5D2-5F8E-4184-A9F6-A92E5D9497A0Q40172843-7FFFE15F-0543-42B2-B75F-C2F8A14420B4Q40941203-77638EA7-3EF1-4D14-9A95-A8AF6F2D4341Q44467757-C520FCAC-36B9-44C7-B2B7-7A73FAEB6737Q44560809-69BEC82D-9954-476D-9267-39756BF97B50Q44605114-061EBA13-7313-4DD3-BBFB-9490461D93BBQ44966770-F99297A5-C0E6-41BE-8A67-840BAC94B998Q45071284-ABCD9834-AFF5-42A9-AD15-5C091236F978Q46161858-F766B320-39E9-4DD8-8314-2DC2A6EFBEC9Q51555074-BC5453C5-0C6A-46C2-B54E-3B3D039F97DDQ53094071-79673DEA-C53C-407E-9EAC-A5844132B9C0Q57786302-C9C3631B-E00B-4524-91BA-CFFC84E2875AQ58910365-B942C6FA-06E1-4B7E-AC08-47CA33C6B617Q84942885-0E2DD8CA-517A-45E3-9530-6785A32087F1Q85803840-3AE4F1EC-7538-4A5A-912D-9018E9FBB1FEQ86942867-FF02B3FD-356A-45D6-B5DB-16FA37193E55Q87114362-11008D4A-AF31-4678-AF30-B6671F1436F3Q87250609-DBF70E4E-31E4-4100-A510-9AC273F14651Q87594038-F1A9DC55-6337-4514-BEB3-DB3ED40E7365
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Marco Morsolini
@ast
Marco Morsolini
@en
Marco Morsolini
@es
Marco Morsolini
@nl
type
label
Marco Morsolini
@ast
Marco Morsolini
@en
Marco Morsolini
@es
Marco Morsolini
@nl
prefLabel
Marco Morsolini
@ast
Marco Morsolini
@en
Marco Morsolini
@es
Marco Morsolini
@nl
P106
P1153
15023182600
P21
P31
P496
0000-0001-5060-9357